Skip to main content

Table 1. Twenty-seven reported cases of IFN-α-induced sarcoidosis [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28].

From: Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

   Patients (n) Proportion of patients (%)
Primary diseases Chronic hepatitis C 24 88.9
  Melanoma 2 7.4
  Erythrocytosis 1 3.7
Sex Male 12 44.4
  Female 15 55.6
Age of sarcoidosis onset
(mean ± standard deviation)
Overall: 51.4 ± 10.8 years
Men: 48.3 ± 9.9 years
Women: 53.9 ± 11.1 years
Treatment IFN-α + ribavirin 21 77.8
  IFN-α 4 14.8
  IFN-α + ribavirin + others 2 7.4
Period until onset 7.9 months (n = 24)
(range, 2–14 months)
Organ involvement Skin 23 85.1
  Lung* 19 70.1
  Lymphadenopathy (mediastinal) 11 40.7
  Lymphadenopathy (hilar) 11 40.7
  Lymphadenopathy (axillary) 11 40.7
  Eye 4 14.8
  Other (heart, liver, central nervous system, retroperitoneal lymphadenopathy, stomach, thyroid) 3
Each 1
11.1
Each 3.7
Therapy Discontinuation of IFN 16 59.2
  Continuation of IFN 2 25.9
  Already completed IFN treatment 2 7.4
  Unknown 2 7.4
  Topical steroid 10 37.0
  Oral steroid 8 29.6
  Steroid pulse 2 7.4
  Others (permanent cardiac pacemaker) 1 3.7
Outcome Resolution 15 55.6
  Improvement 8 29.6
  No change 2 7.4
  Death 1 3.7
  Unknown 1 3.7
  1. IFN interferon, n number
  2. * with or without mediastinal and/or hilar lymphadenopathy